

Special Issue

Advancing the Development and Accessibility of Vaccines Against Bacterial and Viral Pathogens in Low- and Middle-Income Countries (LMICs)

Message from the Guest Editors

In light of ongoing global health disparities, there is a critical need to advance research into vaccines that are specifically tailored for low- and middle-income countries (LMICs) in order to promote equitable health outcomes. This Special Issue seeks to highlight innovative research and practical solutions led by researchers from low- and middle-income countries (LMICs) to address vaccine development challenges, with a particular focus on multidrug-resistant pathogens and context-specific vaccine delivery. We welcome studies employing cutting-edge technologies such as artificial intelligence, case studies on overcoming vaccine distribution barriers, and efforts to correct epistemic injustice by amplifying the voices of researchers from LMICs. Our goal is to provide a focused platform that drives innovation in the development of vaccines tailored to the unique needs and constraints of LMIC settings. We look forward to your contributions to the advancement of equitable vaccine research and the improvement of global health.

Guest Editors

Dr. Ahmed Mostafa

Host-Pathogen Interaction Program, Texas Biomedical Research Institute, San Antonio, TX, USA

Dr. Sherif Abouelhadid

School of Biotechnology, Nile University, Giza, Egypt

Deadline for manuscript submissions

30 September 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/251405

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).